Skip to main content
Contact Us
Subscribe
E-Edition
71°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neogenomics Inc
(NQ:
NEO
)
13.53
-0.24 (-1.74%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Neogenomics Inc
< Previous
1
2
3
4
5
6
Next >
NeoGenomics Announces Senior Leadership Promotions
April 18, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
April 09, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
March 27, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Reports Third Quarter 2023 Results
November 06, 2023
Via
ACCESSWIRE
NeoGenomics Reports Second Quarter 2023 Results
August 08, 2023
Via
ACCESSWIRE
NeoGenomics Reports First Quarter 2023 Results
May 08, 2023
Via
ACCESSWIRE
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
March 20, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Participate in the TD Cowen 44th Annual Health Care Conference
March 01, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Reports Fourth Quarter and Full Year 2023 Results
February 20, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics Signs Working with Cancer Pledge in Support of Employees
February 01, 2024
From
NeoGenomics, Inc.
Via
Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
January 30, 2024
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END
Via
FinancialNewsMedia
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
January 30, 2024
From
FN Media Group LLC
Via
GlobeNewswire
NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024
January 30, 2024
From
NeoGenomics, Inc.
Via
Business Wire
ROSEN, A LEADING NATIONAL FIRM, Encourages NeoGenomics, Inc. Investors to Inquire About Securities Class Action Investigation – NEO
January 02, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
NeoGenomics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
NeoGenomics, Inc.
Via
Business Wire
NeoGenomics to Appeal Ruling
December 28, 2023
Via
ACCESSWIRE
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
December 05, 2023
Via
ACCESSWIRE
NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference
November 14, 2023
Via
ACCESSWIRE
NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios
October 24, 2023
Via
ACCESSWIRE
NeoGenomics to Report Third Quarter 2023 Financial Results on November 6, 2023
October 17, 2023
Via
ACCESSWIRE
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
October 17, 2023
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END
Via
FinancialNewsMedia
NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer
July 27, 2023
Via
ACCESSWIRE
NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023
July 18, 2023
Via
ACCESSWIRE
NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors
June 29, 2023
Via
ACCESSWIRE
NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
June 15, 2023
Via
ACCESSWIRE
NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer
June 05, 2023
Via
ACCESSWIRE
NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
June 01, 2023
Via
ACCESSWIRE
NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO
May 30, 2023
Via
ACCESSWIRE
NeoGenomics to Participate at the BofA Securities 2023 Healthcare Conference
May 03, 2023
Via
ACCESSWIRE
NeoGenomics, Inc. (NASDAQ:NEO) Long Term Investor Alert: Investigation of Potential Wrongdoing
April 20, 2023
San Diego, CA -- (SBWIRE) -- 04/20/2023 -- An investigation concerning potential breaches of fiduciary duties by certain directors and officers of NeoGenomics, Inc was announced.
Via
SBWire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.